Health Care Provider Guide
For this activity, one student will play the role of a health care provider—specifically, a physician in a primary care clinic. A second “practicing” student will serve in the role of a pharmacy intern on rotation in the clinic. The practicing student’s objective will be to correctly answer a drug information question posed by the health care provider.
The health care provider will begin the encounter by introducing their role and the encounter’s setting before then asking the drug information question below. To provide the most appropriate response, the pharmacy intern will need to ask follow-up questions to learn more about the situational context of the inquiry (in other words, to identify the underlying question). To help the health care provider respond to these clarifying questions, relevant case information is provided on the EMR Patient Snapshot Student Activity that accompanies this activity, as well as in the case scenario below. Guidance and examples of appropriate “in-character” responses to typical questions are included in the additional instructions.
It is crucial to the integrity of the activity that the health care provider provide case information only if prompted accordingly by the pharmacy intern.
Throughout the encounter, the pharmacy intern may utilize drug information resources to determine an answer. The interaction will conclude once the pharmacy intern has documented a response on the Pharmacy Intern Guide and Answer Sheet and has also verbally presented their recommendation(s) to the health care provider.
Drug Information Question
“How do I initiate a patient on Basaglar therapy?” (NOTE: This should be verbally posed to the pharmacy intern exactly as written.)
The health care provider, a physician, is seeing a patient named Jimmy Burgess for a diabetes follow-up appointment. Jimmy is a 37-year-old man with type 2 diabetes, and he recently received notification from his prescription insurance company that Toujeo will no longer be considered a preferred agent on his plan’s formulary. His insurance indicated that Basaglar is now the preferred long-acting insulin on formulary, and so the health care provider and Jimmy agree that switching to the Basaglar is appropriate and necessary.
Jimmy’s diabetes has not been well controlled on his existing regimen (metformin 1000 mg BID and Toujeo 50 units every night at bedtime). His A1c, measured 3 weeks ago, is 9%, which is above his goal of <7%. His fasting (morning) glucose readings have ranged from 160 to 220 mg/dL over the last couple of weeks, and he does not take any post-prandial readings. He denies any signs, symptoms, or BG readings indicative of low blood sugar for about the last year.